Overview

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Status:
Active, not recruiting

Trial end date:
2020-08-31

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of intravenous RC48-ADC in local advanced or metastatic gastric patients with the overexpression of HER2.

Phase:

Phase 2

Details

Lead Sponsor:

RemeGen
RemeGen Co., Ltd.

Treatments:

Antibodies
Antibodies, Monoclonal
Trastuzumab